forecast

Moving from GBM to larger markets multiplies addressable patients

The company's growth opportunity is to penetrate the remaining 60 percent of eligible US GBM patients and then expand to much larger cancers, such as roughly 200,000 new lung cases and 40,000 pancreatic cases, plus breast and international markets.

forecastpending

Speaker

Bill

Evidence Quote

“So non-small cell lung cancer, 200,000. Pancreatic, 40,000”

Source

Novocure: Using Physics to Fight Cancer— Business Breakdowns
Created: 11/19/2026, 2:27:17 AM

Your notes

Loading notes...